UNAIDS 2019, Reference
This edition of UNAIDS data shows the results of some of those successes, but also the challenges that remain. It contains the very latest data on the world’s response to HIV, consolidating a small part of the huge volume of data collected, analysed and refined by UNAIDS ov...er the years. The full data set of information for 1990 to 2018 is available on aidsinfo.unaids.org.
more
31 Janaury 2021
SCORE for health data technical package. The first global assessment on the status and capacity of health information systems in 133 countries, covering 87% of the global population.
It identifies gaps and provides guidance for investment in areas that can have the greatest impact ...on the quality, availability, analysis, accessibility and use of health data.
more
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-
aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and
elimination program...s. There is now a priority to ensure that the drug reaches all at-risk PSAC
in endemic areas, including hard-to-reach areas and populations. This study aimed to deter-
mine schistosomiasis treatment-related contextual factors among fishermen and island popu-
lations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.
more
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
Pharmaceutical residues occur globally in the environment. This is demonstrated in the updated database “PHARMS-UBA”. Residues of pharmaceuticals in the environment have been measured in 89 countries in all UN regions. For Germany, 414 active substances or their transformation products were repo...rted, 749 for the European Union and 992 worldwide.
more
Nigeria is Africa’s most populous nation and accounts for nearly one quarter of the continent’s maternal, newborn and child deaths. In the spirit of the global Countdown to 2015 for Maternal, Newborn and Child Health and the Nigerian Saving One Million Lives Initiative, these state data profiles... have been designed to prompt and inform policy and programme action.
Without data there can be no accountability. Without accountability we risk making no progress for Nigeria’s women and children. The data included in these profiles come mainly from large-scale, periodic household surveys. Continued efforts are needed to strengthen civil registration, vital statistics and health management information systems, as well as the institutional capacity to gather and use these data.
Updated from 2011, these data profiles can be used to compare progress in different areas, identify opportunities to address specific coverage gaps, and monitor implementation.
more
This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is
a key component of leprosy treatment, as it is vital to prevent the progression of the infection.
Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with
the ...leprosy infection. Furthermore, the relapse rate is very low, at about 1% over 5–10 years.
There is little M. leprae drug resistance in leprosy and few reports of multi-drug resistance (1, 2, 3,
4, 5, 6, 7, 8). An antibiotic treatment may take months or years to produce clinical improvement,
especially in patients with an initial high bacterial index (BI).
more
Background
Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death.
Methods
This review is based on articles retrieved by a selective search in PubMed, as well as on r...elevant guidelines.
Results
Evidence-based treatment options are available only for congestive heart failure with a low ejection fraction. Pharmacotherapy is based on neurohumoral inhibition of the renin-angiotensin-aldosterone system and the adrenergic system. The prognosis of patients with this condition has been further improved recently through the introduction of combined angiotensin receptor antagonists and neprilysin inhibitors. Modern implantable devices are a further component of treatment. Implantable defibrillators and special pacemakers for cardiac resynchronization are well established; the utility of alternative devices (baroreflex modulation or cardiac contractility modulation) needs to be investigated in further studies. It was recently shown that the catheter-based treatment of secondary mitral regurgitation with a MitraClip improves the outcome of selected patients.
Conclusion
The treatment of chronic systolic heart failure as recommended in the relevant guidelines, with drugs and implanted devices if indicated, can significantly improve the clinical outcome.
more
Effective antibiotics are essential for childrens’ survival
Working Document, September 2017
Research Article
BMC Infectious Diseases 2012, 12:262; doi:10.1186/1471-2334-12-262